Search Within

Chau Dang

Formats
  1. Journal Article (132)
  2. Meeting Abstract (122)
  3. Guidelines (8)
  4. Book Section (4)
  5. Review (3)
  6. Book Whole (1)
  7. Editorial (1)
  8. Miscellaneous (1)
  9. Research Letter (1)
Groups
  1. Breast Medicine Service (273)
  2. Department of Medicine (273)
  3. Solid Tumor Oncology Division (273)
  4. Survivorship Research (273)
  5. Population Sciences Research Program (119)
  6. Epidemiology and Biostatistics (93)

More Groups

People
  1. Clifford Hudis (111)
  2. Larry Norton (76)
  3. Richard Steingart (49)
  4. Anthony Yu (46)
  5. Shanu Modi (42)
  6. Sujata Patil (41)

More People

Years
  1. 2025 (4)
  2. 2024 (12)
  3. 2023 (15)
  4. 2022 (18)
  5. 2021 (12)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (68)
  2. Cancer Research (42)
  3. Breast Cancer Research and Treatment (23)
  4. Annals of Oncology (10)
  5. Clinical Breast Cancer (7)
  6. Clinical Cancer Research (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (70)
  2. American Association for Cancer Research (50)
  3. Springer (33)
  4. Oxford University Press (22)
  5. Elsevier Inc. (16)
  6. American Medical Association (11)

More Publishers

Results (273)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced ejection fraction
    Meeting Abstract

    Hussain, Y.; Dang, C.; Steingart, R.; Liu, J.; Yu, A. F.
    Journal of the American College of Cardiology (2018)

    Fulltext@MSK | Save
  • Prospective evaluation of circulating biomarkers as predictors of cardiotoxicity in patients with HER2-positive breast cancer receiving anthracyclines and trastuzumab
    Meeting Abstract

    Yu, A. F.; Knezevic, A.; Moskowitz, C.; Dang, C.; Ramanathan, L.; Oeffinger, K.; Liu, J.; Steingart, R.
    Journal of the American College of Cardiology (2018)

    Fulltext@MSK | Save
  • Chemotherapy with and without trastuzumab or no treatment in elderly patients with HER2 amplified breast cancer at a single center
    Meeting Abstract

    Muhsen, S.; Dang, C.; Plitas, G.; Seier, K.; Stempel, M.; Patil, S.; Morrow, M.; El-Tamer, M.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Frequency of delivery of systemic chemotherapy in elderly versus younger patients with triple negative breast cancer
    Meeting Abstract

    Muhsen, S.; Dang, C.; Plitas, G.; Knezevic, A.; Stempel, M.; Patil, S.; Morrow, M.; El-Tamer, M.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer
    Meeting Abstract

    Sparano, J. A.; O'Neill, A.; Alpaugh, K.; Wolff, A. C.; Northfelt, D. W.; Dang, C.; Sledge, G. W. Jr.; Miller, K. D.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Immune profile of small HER2+ tumors in the APT trial
    Meeting Abstract

    Tolaney, S. M.; Barry, W.; Guo, H.; Dillon, D.; Tan, Y. B.; Fuhrman, K.; Osmani, W.; Getz, A.; Baltay, M.; Dang, C.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab
    Meeting Abstract

    Krop, I. E.; Hillman, D.; Polley, M. Y.; Tanioka, M.; Parker, J.; Huebner, L.; Henry, N. L.; Tolaney, S. M.; Dang, C.; Harris, L.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study
    Meeting Abstract

    Dang, C.; Ewer, M. S.; Delaloge, S.; Ferrero, J. M.; Verrill, M.; Colomer, R.; Vieira, C.; de la Cruz Merino, L.; Lucas, J.; Werner, T. L.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer
    Meeting Abstract

    Wang, R.; Yu, A. F.; Steingart, R.; Patil, S.; Baselga, J.; Norton, L.; Hudis, C.; Dang, C. T.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)
    Meeting Abstract

    Tolaney, S. M.; Barry, W. T.; Guo, H.; Dillon, D.; Dang, C. T.; Yardley, D. A.; Moy, B.; Marcom, P. K.; Albain, K. S.; Rugo, H. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save